↓ Skip to main content

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

Overview of attention for article published in BMC Geriatrics, January 2005
Altmetric Badge

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
48 Mendeley